Cargando…
Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma
SIMPLE SUMMARY: Neurofibromatosis type 2 (NF2) is a rare genetic hereditary disease characterized by multiple central nervous system tumors, most frequently bilateral vestibular schwannomas (VSs). No chemotherapeutic agents are available for clinical use, and surgery and radiotherapy are the only th...
Autores principales: | Fujii, Masazumi, Kobayakawa, Masao, Saito, Kiyoshi, Inano, Akihiro, Morita, Akio, Hasegawa, Mitsuhiro, Mukasa, Akitake, Mitsuhara, Takafumi, Goto, Takeo, Yamaguchi, Shigeru, Tamiya, Takashi, Nakatomi, Hirofumi, Oya, Soichi, Takahashi, Fumiaki, Sato, Taku, Bakhit, Mudathir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985777/ https://www.ncbi.nlm.nih.gov/pubmed/33572546 http://dx.doi.org/10.3390/curroncol28010071 |
Ejemplares similares
-
Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients
por: FUJII, Masazumi, et al.
Publicado: (2020) -
Current progress in genomics and targeted therapies for neurofibromatosis type 2
por: Hiruta, Ryo, et al.
Publicado: (2023) -
Long-Term Outcomes of Stereotactic Radiosurgery for Vestibular Schwannoma Associated with Neurofibromatosis Type 2 in Comparison to Sporadic Schwannoma
por: Shinya, Yuki, et al.
Publicado: (2019) -
Intraoperative quantification of meningioma cell proliferation potential using rapid flow cytometry reveals intratumoral heterogeneity
por: Oya, Soichi, et al.
Publicado: (2019) -
New developments in neurofibromatosis type 2 and vestibular schwannoma
por: Ren, Yin, et al.
Publicado: (2020)